[170 Pages Report] The Rare Inflammatory Disease Treatment Market has garnered a market value of US$ 12,664 Million in 2021, anticipated to register a positive CAGR of 4.6% in the forecast period 2022 to 2028 and reach a value of US$ 17,335.8 Million.
| Attribute | Details |
|---|---|
| Rare Inflammatory Disease Treatment Market Size (2022) | US$ 13,249.2 Million |
| Projected Market Value (2028) | US$ 17,335.8 Million |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Region With Dominant Market Share | North America |
Increasing investment in R&D for various drug developments and increasing demand for different modes of drug administration have further boosted the market demand for various rare inflammatory diseases treatments.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.35% |
| H1, 2022 Projected | 8.82% |
| H1, 2022 Outlook | 8.52% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 30 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (+) 17 ↑ |
A comparative analysis related to the market growth rates and development prospects in the global rare inflammatory disease treatment market is presented by Future Market Insights. The market is highly influenced by the onerous regulatory environment and innovation factors for orphan drugs under the impact of macro and industry factors.
According to Future Market Insights analysis, the global rare inflammatory disease treatment market expects to surge by 17 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during H1-2022 outlook period will show a dip of 30 BPS.
The market change in the BPS is associated with the extensive process of orphan drug approval by regulatory bodies for licensure and distribution. Further, revision in molecular portfolio for existing products also face a backlash in terms of patent renewal, owed to the emergence of several clinically viable alternatives to existing solutions.
This has caused a reduction in the BPS value. Additionally, the growth of the biopharmaceutical industry upon the advent of the COVID-19 pandemic has provided a boost in the BPS value change for the market.
The market is subject to activities such as supporting the treatment of rare diseases through collaborative activities, revenue fluidity which arises from product Medicaid rebates, chargebacks due to other government programs, and existing patented product portfolio.
From 2013 to 2021, treatment for rare inflammatory diseases experienced an increase of 3.8% in value CAGR terms. Various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies have observed high demand for treating several rare inflammatory diseases. Recent outbreaks of infectious diseases, such as COVID-19, have increased market demand to a major extent.
During the height of the pandemic crisis, clinicians, doctors and other healthcare stakeholders extensively relied on anti-inflammatory drugs to ease complications experienced by severely infected and immunocompromised patients. Drugs such as ibuprofen, for instance, was cleared by the National Health Service in the U.K to be used as a nonsteroidal anti-inflammatory drug (NSAID) to inhibit receptors responsible for triggering an inflammatory response to the coronavirus.
Companies have been considering in their production processes ways to improve the treatment of rare inflammatory diseases, such as eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder that causes vasculitis. One such treatment is Nucala, a medication for patients aged 6 years or older with relapsing-remitting or refractory EGPA. Likewise, several orphan drugs are coming into the limelight for numerous rare inflammatory diseases. Overall, demand for rare inflammatory disease treatment is anticipated to rise at a CAGR of around 4.6% through 2028.
Healthcare experts have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.
Moreover, the occurrence of inflammatory and autoimmune diseases is increasing at a rapid pace. According to the World Health Organization, psoriasis affects approximately 100 million people globally, while between 1.3% and 34.7% develop chronic and inflammatory arthritis. Likewise, inflammatory bowel infections such as ulcerative colitis and Crohn’s disease are increasing at an alarming rate in formerly unaffected fragments of the world.
Hence, medical practitioners are introducing several drug candidates to address some of the most debilitating rare inflammatory diseases. In 2018, for instance, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted an extension of indication to Kineret (anakinra) for treating Still's disease. Kineret is an immunosuppressive medicine which inhibits chemical messenger activity of interleukin-1, an agent which is produced in excess amongst patients suffering from rheumatoid arthritis and juvenile idiopathic arthritis.
Principal Consultant
FMI forecasts the rare inflammatory disease treatment industry in North America to accumulate a market share of 39.9% in 2022. The presence of a well-developed health care system and several reimbursement programs aimed at facilitating access to treatment for those with rare illnesses are among the chief growth drivers.
More than 30 million Americans are afflicted with rare diseases. Every year, approximately 6,200 Americans are affected diseases, including Polycythemia Vera, while juvenile rheumatoid arthritis is one of the most common types of arthritic diseases that children are diagnosed with in the United States.
Demand for rare inflammatory disease treatment has risen through various distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. As a result, the U.S. is expected to account for the largest market share in the market for rare inflammatory diseases treatment.
D of new treatments and advancements in medical technology have driven market demand for rare inflammatory disease treatment throughout Europe. With increasing investments in open-source drug delivery systems and evaluations of their effectiveness in treating rare diseases, more treatment options are becoming available for rare inflammatory diseases.
Recently, in September 2021, the European Medicines Agency has recommended granting an extension of indication to Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA), responsible for inflaming vital organs such as the lungs, heart, skin, nervous system and gastrointestinal tract.
It is estimated that between 0.18 and 4 new cases per 1 million are diagnosed each year with EGPA. The drug is already approved for treating patients of the same age group for eosinophilic asthma. According to FMI, rare inflammatory disease treatment in Europe is like to accumulate a market share of 24% in 2022.
Due to the significant cost savings associated with ulcerative colitis treatments, the producers will be influenced to increase their manufacturing capacities for advanced drugs and therapies in the future.
Technological advancements and the increasing number of patients suffering from ulcerative colitis have contributed to the development of advanced treatments for ulcerative colitis. The influx of new therapeutics methods, demand for enhancing drugs, and advances in treating ulcerative colitis have propelled market demand for rare inflammatory diseases treatments.
The growing prevalence of diseases and demand for 24/7 medication sales have catalyzed the global market demand for drugs at retail pharmacies. Future growth in artificial intelligence, advanced analytics, and other technologies will help drive the retail pharmacy market in the global market.
Health and wellness services are the key drivers of customer satisfaction at brick-and-mortar pharmacies. These services score 66 points higher than other types of services. Pharmacies with these services are present in 86% of chain pharmacies, 83% of supermarkets, and 75% of mass merchandisers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Prominent treatment providers are emphasizing on advancing drug and treatment offerings by initiating a series of clinical studies as well as forging collaborative and acquisition agreements with existing pharmaceutical companies.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Rare Inflammatory Disease Treatment by Indication
Rare Inflammatory Disease Treatment by Drug Class
Rare Inflammatory Disease Treatment by Mode of Administration
Rare Inflammatory Disease Treatment by Distribution Channel
Rare Inflammatory Disease Treatment Market by Region
In 2022, the global rare inflammatory disease treatment market is set to be net US$ 13,249.2 Mn.
FMI Analysts predict the rare inflammatory disease treatment market to attain an estimated worth of US$ 17,335.8 Mn by 2028
North America will hold the highest global market share of 39.9% in 2022
The rare inflammatory disease treatment industry to rise at a CAGR of 4.6% from 2022 to 2028
1. Global Economic Outlook 2. Global Rare Inflammatory Disease Treatment Market - Executive Summary 3. Global Rare Inflammatory Disease Treatment Market Overview 3.1. Introduction 3.1.1. Global Rare Inflammatory Disease Treatment Market Taxonomy 3.1.2. Global Rare Inflammatory Disease Treatment Market Definition 3.2. Global Rare Inflammatory Disease Treatment Market Size (US$ Mn) and Forecast, 2013-2028 3.2.1. Global Rare Inflammatory Disease Treatment Market Y-o-Y Growth 3.3. Global Rare Inflammatory Disease Treatment Market Dynamics 3.4. Supply Chain 3.5. Cost Structure 3.6. Pricing Analysis 3.7. Forecast Scenario 3.8. Parent Market Overview 3.9. PEST Analysis 3.10. Porter's Five Forces Analysis 3.11. Key Regulations 3.11.1. Key Regulations - North America 3.11.2. Key Regulations - Latin America 3.11.3. Key Regulations - Europe 3.11.4. Key Regulations - Asia Pacific 3.11.5. Key Regulations - Middle East & Africa 3.12. Product Approvals in Rare Inflammatory Disease Treatment Market 3.13. Investment Feasibility Index 3.14. Market Competition Structure 3.15. Market Positioning and Behaviour Assessment 3.16. List of Distributors 3.17. Key Participants Market Presence (Intensity Map) By Region 4. Global Rare Inflammatory Disease Treatment Market Analysis and Forecast 2013-2028 4.1. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Indication, 2013-2028 4.1.1. Ulcerative Colitis Market Size and Forecast, 2013-2028 4.1.1.1. Revenue (US$ Mn) Comparison, By Region 4.1.1.2. Market Share Comparison, By Region 4.1.1.3. Y-o-Y growth Comparison, By Region 4.1.2. Juvenile Rheumatoid Arthritis Market Size and Forecast, 2013-2028 4.1.2.1. Revenue (US$ Mn) Comparison, By Region 4.1.2.2. Market Share Comparison, By Region 4.1.2.3. Y-o-Y growth Comparison, By Region 4.1.3. Psoriatic Arthritis Market Size and Forecast, 2013-2028 4.1.3.1. Revenue (US$ Mn) Comparison, By Region 4.1.3.2. Market Share Comparison, By Region 4.1.3.3. Y-o-Y growth Comparison, By Region 4.1.4. Other Indications Market Size and Forecast, 2013-2028 4.1.4.1. Revenue (US$ Mn) Comparison, By Region 4.1.4.2. Market Share Comparison, By Region 4.1.4.3. Y-o-Y growth Comparison, By Region 4.2. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Drug Class, 2013-2028 4.2.1. Biologics Market Size and Forecast, 2013-2028 4.2.1.1. Revenue (US$ Mn) Comparison, By Region 4.2.1.2. Market Share Comparison, By Region 4.2.1.3. Y-o-Y growth Comparison, By Region 4.2.2. Organic Compounds Market Size and Forecast, 2013-2028 4.2.2.1. Revenue (US$ Mn) Comparison, By Region 4.2.2.2. Market Share Comparison, By Region 4.2.2.3. Y-o-Y growth Comparison, By Region 4.3. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Mode of Administration, 2013-2028 4.3.1. Injectables Market Size and Forecast, 2013-2028 4.3.1.1. Revenue (US$ Mn) Comparison, By Region 4.3.1.2. Market Share Comparison, By Region 4.3.1.3. Y-o-Y growth Comparison, By Region 4.3.2. Oral Market Size and Forecast, 2013-2028 4.3.2.1. Revenue (US$ Mn) Comparison, By Region 4.3.2.2. Market Share Comparison, By Region 4.3.2.3. Y-o-Y growth Comparison, By Region 4.3.3. Others Market Size and Forecast, 2013-2028 4.3.3.1. Revenue (US$ Mn) Comparison, By Region 4.3.3.2. Market Share Comparison, By Region 4.3.3.3. Y-o-Y growth Comparison, By Region 4.4. Global Rare Inflammatory Disease Treatment Market Size and Forecast By Distribution Channel, 2013-2028 4.4.1. Hospital Pharmacies Market Size and Forecast, 2013-2028 4.4.1.1. Revenue (US$ Mn) Comparison, By Region 4.4.1.2. Market Share Comparison, By Region 4.4.1.3. Y-o-Y growth Comparison, By Region 4.4.2. Retail Pharmacies Market Size and Forecast, 2013-2028 4.4.2.1. Revenue (US$ Mn) Comparison, By Region 4.4.2.2. Market Share Comparison, By Region 4.4.2.3. Y-o-Y growth Comparison, By Region 4.4.4. Market Size and Forecast, 2013-2028 4.4.4.1. Revenue (US$ Mn) Comparison, By Region 4.4.4.2. Market Share Comparison, By Region 4.4.4.3. Y-o-Y growth Comparison, By Region 5. North America Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 5.1. North America Outlook 5.2. North America Parent Market Outlook 5.3. North America Target Market Outlook 5.4. Revenue (US$ Mn) Comparison, By Country 5.4.1. US Market Size and Forecast (US$ Mn), 2013-2028 5.4.2. Canada Market Size and Forecast (US$ Mn), 2013-2028 5.5. Revenue (US$ Mn) Comparison, By Indication 5.6. Revenue (US$ Mn) Comparison, By Drug Class 5.7. Revenue (US$ Mn) Comparison, By Mode of Administration 5.8. Revenue (US$ Mn) Comparison, By Distribution Channel 6. Latin America Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 6.1. Latin America Outlook 6.2. Latin America Parent Market Outlook 6.3. Latin America Target Market Outlook 6.4. Revenue (US$ Mn) Comparison, By Country 6.4.1. Brazil Market Size and Forecast (US$ Mn), 2013-2028 6.4.2. Mexico Market Size and Forecast (US$ Mn), 2013-2028 6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2013-2028 6.5. Revenue (US$ Mn) Comparison, By Indication 6.6. Revenue (US$ Mn) Comparison, By Drug Class 6.7. Revenue (US$ Mn) Comparison, By Mode of Administration 6.8. Revenue (US$ Mn) Comparison, By Distribution Channel 7. Europe Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 7.1. Europe Outlook 7.2. Europe Parent Market Outlook 7.3. Europe Target Market Outlook 7.4. Revenue (US$ Mn) Comparison, By Country 7.4.1. Germany Market Size and Forecast (US$ Mn), 2013-2028 7.4.2. U.K. Market Size and Forecast (US$ Mn), 2013-2028 7.4.3. Spain Market Size and Forecast (US$ Mn), 2013-2028 7.4.4. France Market Size and Forecast (US$ Mn), 2013-2028 7.4.5. Italy Market Size and Forecast (US$ Mn), 2013-2028 7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2013-2028 7.5. Revenue (US$ Mn) Comparison, By Indication 7.6. Revenue (US$ Mn) Comparison, By Drug Class 7.7. Revenue (US$ Mn) Comparison, By Mode of Administration 7.8. Revenue (US$ Mn) Comparison, By Distribution Channel 8. Japan Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 8.1. Japan Outlook 8.2. Japan Parent Market Outlook 8.3. Japan Target Market Outlook 8.4. Japan Market Size and Forecast (US$ Mn), 2013-2028 8.5. Revenue (US$ Mn) Comparison, By Indication 8.6. Revenue (US$ Mn) Comparison, By Drug Class 8.7. Revenue (US$ Mn) Comparison, By Mode of Administration 8.8. Revenue (US$ Mn) Comparison, By Distribution Channel 9. APEJ Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 9.1. APEJ Outlook 9.2. APEJ Parent Market Outlook 9.3. APEJ Target Market Outlook 9.4. Revenue (US$ Mn) Comparison, By Country 9.4.1. China Market Size and Forecast (US$ Mn), 2013-2028 9.4.2. India Market Size and Forecast (US$ Mn), 2013-2028 9.4.3. Malaysia Market Size and Forecast (US$ Mn), 2013-2028 9.4.4. Singapore Market Size and Forecast (US$ Mn), 2013-2028 9.4.5. Australia Market Size and Forecast (US$ Mn), 2013-2028 9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2013-2028 9.5. Revenue (US$ Mn) Comparison, By Indication 9.6. Revenue (US$ Mn) Comparison, By Drug Class 9.7. Revenue (US$ Mn) Comparison, By Mode of Administration 9.8. Revenue (US$ Mn) Comparison, By Distribution Channel 10. MEA Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 10.1. MEA Outlook 10.2. MEA Parent Market Outlook 10.3. MEA Target Market Outlook 10.4. Revenue (US$ Mn) Comparison, By Country 10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2013-2028 10.4.2. South Africa Market Size and Forecast (US$ Mn), 2013-2028 10.4.3. Israel Market Size and Forecast (US$ Mn), 2013-2028 10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2013-2028 10.5. Revenue (US$ Mn) Comparison, By Indication 10.6. Revenue (US$ Mn) Comparison, By Drug Class 10.7. Revenue (US$ Mn) Comparison, By Mode of Administration 10.8. Revenue (US$ Mn) Comparison, By Distribution Channel 11. Global Rare Inflammatory Disease Treatment Market Company Share, Competition Landscape and Company Profiles 11.1. Global Rare Inflammatory Disease Treatment Market- Company Share Analysis 11.2. Global Rare Inflammatory Disease Treatment Market - Competition Landscape 11.3. Global Rare Inflammatory Disease Treatment Market - Company Profiles 11.3.1. Pfizer, Inc. 11.3.2. Novartis AG 11.3.3. Allergan Plc 11.3.4. Abbvie, Inc. 11.3.5. Valeant Pharmaceuticals International, Inc. 11.3.6. Abbott Laboratories 11.3.7. Johnson & Johnson 11.3.8. Regeneron Pharmaceuticals, Inc. 11.3.9. Mallinckrodt Plc 11.3.10. Swedish Orphan Biovitrum AB 12. Global Rare Inflammatory Disease Treatment Market - Key Takeaways 13. Research Methodology 14. Disclaimer
Explore Healthcare Insights
View Reports
Rare Inflammatory Disease Treatment Market
